By admin | March 14, 2010
An army of 19 new and newly secured care advisors will be joining the fight against muscle disease across the UK with the Muscular Dystrophy Campaign…
By admin | March 11, 2010
What Families living with muscle disease in the East of England are joining forces with clinicians and MPs at an inaugural conference for the region, organised by the Muscular Dystrophy Campaign. The conference will be an opportunity for families to learn more about fighting for better muscle disease services in their region and to find out how local campaigning can make a real difference…
Spinal Muscular Atrophy (SMA) is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis…
‘Muscle Gene Therapy’ brings together the latest research in this promising field.
ALS TDI’s first-quarter 2010 research update can be summed up with one word: momentum.
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig’s disease also known as familial amyotrophic lateral sclerosis (ALS). Approximately 20 percent of all familial ALS cases are caused by a mutant form of superoxide dismutase, or SOD1…
Human testing has begun of ISIS-SOD1-Rx, a compound designed to block production of a toxic protein in people with the SOD1-related form of familial (inherited) ALS
Human testing has begun of ISIS-SOD1-Rx, a compound designed to block production of a toxic protein in people with the SOD1-related form of familial (inherited) ALS
The experimental drug ataluren, developed to overcome nonsense mutations in Duchenne and Becker MD, did not meet its primary end point in a large-scale human trial.
A research team reports “unprecedented” improvement in newborn SMA-affected mice that received gene therapy via intravenous injection.
